Grade 3–4 treatment-related adverse events occurred in 18% of patients, with the most common being thrombocytopenia, neutropenia, and anemia, consistent with high levels of CD47 expression on platelets, neutrophils, and RBCs, respectively. This evidence concerns the gene CD47 and anemia.